Please ensure Javascript is enabled for purposes of website accessibility

Why Corbus Pharmaceuticals Holdings Is Flying High Today

By Keith Speights – Updated Sep 20, 2018 at 3:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A licensing deal that boosts its pipeline provided a big catalyst for this clinical-stage biotech.

What happened

Shares of Corbus Pharmaceuticals Holdings (CRBP 1.88%) were up 40.1% as of 11:34 a.m. EDT on Thursday. The biotech announced earlier in the day that it had signed a deal with Jenrin Discovery LLC for exclusive worldwide rights to develop and market drugs based on more than 600 compounds targeting the endocannabinoid system.

So what

The licensing deal with Jenrin Discovery was huge for Corbus because it provides a big boost to the biotech's pipeline. Corbus previously had only one pipeline candidate -- lenabasum (formerly known as anabasum). The drug is currently in a phase 3 clinical study targeting the treatment of systemic sclerosis, a rare autoimmune disease. Corbus also plans to start another phase 3 study of lenabasum for treating dermatomyositis by the end of this year after reporting positive phase 2 results for the drug last year.

Female scientist looking through microscope with another scientist holding dropper

Image source: Getty Images.

Now, though, Corbus instantly has another candidate in its pipeline, CRB-4001. Like lenabasum, CRB-4001 targets the endocannabinoid system. But while lenabasum binds to cannabinoid receptor 2 (CB2), CRB-4001 is a cannabinoid receptor 1 (CB1) inverse agonist that interacts with CB1 receptors outside of the brain.

Corbus plans to advance CRB-4001 to a phase 1 clinical study in 2019. The National Institutes of Health (NIH) has already committed to funding a phase 2 study. CRB-4001 holds potential in treating several liver, lung, heart, and kidney fibrotic diseases, including nonalcoholic steatohepatitis (NASH).

The impact of the deal with Jenrin goes beyond just CRB-4001, though. Corbus CEO Mark Tepper said that the biotech "now has a pipeline that we believe will support the advancement of one to two new drug candidates into clinical testing each year starting in 2020."

Now what

Today's news makes Corbus more attractive than it was with only lenabasum in its pipeline. CRB-4001 appears to be a great fit for the biotech. And NASH is a great indication to target for Corbus.

It's still really early, though. I'd like to see exactly how Corbus moves forward with the clinical program for CRB-4001. Of course, it's also important to find out how well lenabasum fares in its phase 3 study for the treatment of systemic sclerosis. I think Corbus continues to be a biotech stock for investors to watch closely.  

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corbus Pharmaceuticals Holdings, Inc. Stock Quote
Corbus Pharmaceuticals Holdings, Inc.
$0.17 (1.88%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.